Mary T. Szela appointed CEO and President of Surefire Medical

Surefire Medical affirmed the appointment of Mary T. Szela as its CEO, President and a member of the company’s Board Of Directors. James Chomas PhD precedes Szela who served as Surefire’s founder having served since 2009.

Mats Wahlström, Surefire’s Chairman of the Board said “Mary brings the leadership capabilities necessary to fulfill the full potential of what Surefire’s technology can do to transform cancer care on a global scale. Her proven commercial track record, coupled with her passion and commitment to patients, aligns with the company’s mission to better deliver quality of life for cancer patients.”

Szela’s exemplary leadership stints include Chief Executive Officer of Novelion Therapeutics. Additionally, she secured the approval, registration and launch of lomitapide in Japan, oversaw the European filing for metreleptin, and built a clinical development platform to treat multiple diseases using leptin hormone replacement therapy. Prior to Novelion, Szela was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort, accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus). Szela held ascending management positions at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business, developing global brands such as Humira®, and serving as Vice President for global strategic marketing and  services.

Image Source: Surefire Medical